India Pharmas Urge New Government To Take Pro-Pharma Stance
This article was originally published in PharmAsia News
Executive Summary
Indian pharmaceuticals urge the new government to ease up on pricing restrictions and take actions to encourage more industry spending on research and development. Several Indian pharma executives echoed the sentiment that a new government would be favorable to the industry and offered suggestions for reform, greater spending on healthcare and a greater recognition that pharmas need to be seen as part of a growth industry. One executive said the new government should drop proposals to add drugs to be covered under the country's price-control program. (Click here for more
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.